The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Guillermo Garcia-Manero, MD, discusses the phase 3 GLORA-4 study of lisaftoclax plus azacitidine in higher-risk MDS.

Cancer vaccine, NOUS-209 was found to stimulate the immune system and target precancerous cells in Lynch Syndrome according to MD Anderson Cancer center.

Kanwal P.S. Raghav, MBBS, MD, discusses the mechanism of action of telisotuzumab adizutecan in post-adjuvant ctDNA-positive CRC.

Dr Garcia-Manero contextualizes lisaftoclax's potential to improve outcomes historically achieved with azacitidine alone in higher-risk MDS.

Guillermo Garcia-Manero, MD, discusses how updated VERONA trial data showed no OS benefit with venetoclax plus azacitidine vs azacitidine alone in MDS.

Xiuning Le, MD, PhD, discusses the FDA approval of sevabertinib for pretreated, advanced, nonsquamous NSCLC with tumors harboring HER2 TKD mutations.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, breast cancer, and colorectal cancer.

Kanwal P.S. Raghav, MBBS, MD, discusses the rationale for examining telisotuzumab adizutecan in post-adjuvant ctDNA-positive CRC.

Yue Wei, PhD, discussed the role of HMAs in platelet response in MDS and the clinical relevance of using a mouse model to investigate this approach.

Jason Aboudi Mouabbi, MD, discussed the importance of using ctDNA testing to inform treatment decision-making across breast cancer populations.

Andrew W. Hahn, MD, discusses the efficacy and safety of lenvatinib plus everolimus in metastatic ccRCC after progression on PD-1–directed ICIs

Preetesh Jain, MD, MBBS, DM, PhD, discusses data from real-world analysis of treatment patterns in high-risk mantle cell lymphoma and their implications.

Fangfang Yan, MD, discusses the place of CAR T-cell therapy in the MCL treatment paradigm and how AI can address drivers of CAR T-cell therapy resistance.

Embracing the consistency of change allowed Michael Andreeff, MD, PhD, to earn his title as a 2025 Giants of Cancer Care inductee in Translational Science.

Jason Mouabbi, MD, discusses the emerging role of ctDNA tests in breast cancer management and their use in early detection and treatment monitoring.

Richard Gorlick, MD, is a leading physician-scientist whose career and lifelong commitment to improving outcomes for children with cancer has been shaped by his personal journey as a childhood cancer survivor.

The top 5 OncLive TV videos of the week cover insights in ALL, breast cancer, lung cancer, and pancreatic cancer.

Dr Mouabbi highlights the ways that ctDNA has evolved from a research tool to a potential clinical decision-making aid in breast cancer.

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends spanning CML, CLL, B-cell lymphomas, and other hematologic malignancies.

Anito-cel showed deepening responses in patients with relapsed or refractory myeloma enrolled in the phase 2 iMMagine-1 study.

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

Sankalp Arora, MD, discusses the efficacy of azacitidine/venetoclax/gilteritinib in newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia.

Fadi Haddad, MD, discusses the efficacy of asciminib in patients with newly diagnosed chronic myeloid leukemia as seen in a phase 2 trial.

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.

Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Dr Pant discusses factors that drive frontline chemotherapy selection for metastatic pancreatic cancer and the role of NALIRIFOX in this treatment setting.